Clinical trial · no report yet · Phase 1
NCT04479306
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
- NCT04479306 ↗
- Completed
- M.D. Anderson Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Ph1b Study of Osimertinib + Alisertib or Sapanisertib for Osimertinib-Resistant EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) (Crossover Study)
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Alisertib; Osimertinib; Sapanisertib
- Arms
- Arm A (osimertinib, alisertib) · Experimental
- Arm B (osimertinib, sapanisertib) · Experimental
- Enrollment
- 37
- Primary outcomes
- Recommended phase 2 dose (RP2D) of osimertinib and alisertib combination (Arm A)
- RP2D of osimertinib and sapanisertib combination (Arm B)
- Dose-limiting toxicity (DLT)
- Incidence of adverse events
- Sponsor
- M.D. Anderson Cancer Center
- Start
- Jun 18, 2020
- Primary completion
- Jul 27, 2023
- Results posted
- No
- Registry record
- NCT04479306 · updated Apr 16, 2026